You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》瑞德西韋生產商吉利得(GILD.US)季績勝預期 上調全年盈測
新冠治療藥瑞德西韋生產商,美國藥廠吉利得科學(Gilead Sciences)(GILD.US)公佈第二季業績。季度純利11.44億美元,按年跌25%。每股季度攤薄純利91美仙,經調整後爲1.58美元,高於市場預期的1.52美元,季度派息每股73美仙。季度收入62.6億美元,按年升0.7%,高於市場預期的58.5億美元。 瑞德西韋季度銷售按年跌46%至4.45億美元,高於市場預期的3.9億美元。癌症治療藥Trodelvy季度銷售升79%至1.59億美元,癌細胞治療藥銷售按年升68%至3.68億美元。愛滋病藥物銷售按年升7%至42億美元。 公司預期全年經調整每股純利介乎6.35至6.75美元,高於早前預測的介乎6.2至6.7美元。產品銷售預測料介乎245億至250億美元,高於原來預期的238億至243億美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account